New combo therapy for liver cancer: radiation plus immune boost before surgery
NCT ID NCT06994299
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This early-phase study was designed to test a new treatment combination for people with advanced liver cancer that can be surgically removed. Participants would have received three sessions of focused radiation to the tumor, along with immunotherapy drugs (one dose of tremelimumab and regular doses of durvalumab) to help the immune system fight the cancer. The main goals were to check if the combination is safe and whether it shrinks the tumor enough to improve surgery results. However, the study was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New York-Presbyterian Weill Cornell Medical College
New York, New York, 11355, United States
Conditions
Explore the condition pages connected to this study.